Benzinga | May 3, 2021 08:40AM EDT

Denali Therapeutics Q1 EPS $(0.58) Down From $(0.55) YoY, Collaboration Revenue $7.92M Up From $3.60M YoY

Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.58) per share. This is a 5.45 percent decrease over losses of $(0.55) per share from the same period last year. The company reported $7.92 million in sales this quarter. This is a 119.84 percent increase over sales of $3.60 million the same period last year.